BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS will present new data on GLIX1, an oral small molecule targeting the DNA damage response via TET2 activation, at ASCO 2026, including its potential as monotherapy and in combination with PARP inhibitors across multiple cancers. The Phase 1/2a trial for glioblastoma (GBM) was initiated in March 2026, with preclinical studies showing strong antitumor activity and brain penetration in animal models, alongside well-tolerated safety profiles.
BioLineRx Ltd. and Hemispherian AS announced two abstracts on GLIX1, a first-in-class oral small molecule targeting the DNA damage response by restoring TET2 enzyme activity, will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, May 29–June 2, 2026. GLIX1 works by reactivating TET2, which is suppressed in cancer, leading to tumor-selective DNA strand breaks. Preclinical studies demonstrated its efficacy in glioblastoma xenograft models (U87-MG and SNB-19) and confirmed brain penetration with plasma-equivalent exposure in mice. Safety tests in rats and dogs showed no toxicity at doses up to 2000mg/kg and 1000mg/kg, respectively. A Phase 1/2a trial (NCT07464925) for glioblastoma is currently enrolling patients. The first abstract highlights GLIX1’s mechanism—enhancing TET2 activity to induce lethal DNA damage in cancer cells—while the second explores its synergistic potential with PARP inhibitors across multiple cancers. Both presentations emphasize GLIX1’s broad applicability beyond glioblastoma, including metastatic breast cancer. Philip Serlin, CEO of BioLineRx, called the ASCO data ‘compelling,’ noting the trial’s initiation in March 2026 and the strong preclinical rationale. Dr. Adam Robertson, Hemispherian’s Chief Scientific Officer, described GLIX1’s novel approach to targeting the DNA damage response, particularly its ability to trigger tumor-selective toxicity. The abstracts (e14072 and e13129) will be published under ‘Central Nervous System Tumors’ and ‘Breast Cancer/Metastatic’ sessions, respectively. GLIX1’s development aligns with unmet needs in high-grade gliomas, where reduced TET2 activity and 5hmC levels create therapeutic vulnerabilities.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.